Drugs in Dev. Obstetrics/Gynecology (Women’s Health)
Discovery
Lead Product(s) : Certepetide,Bevacizumab
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Discovery
Sponsor : University of Cincinnati
Deal Size : Undisclosed
Deal Type : Agreement
Lisata And Cincinnati University to Research Certepetide for Endometriosis
Details : Through the agreement, Lisata will evaluate a novel cyclic peptide product candidate, LSTA1 (certepetide), in combination with bevacizumab to treat endometriosis.
Brand Name : LSTA1
Molecule Type : Peptide
Upfront Cash : Undisclosed
October 28, 2024
Lead Product(s) : Certepetide,Bevacizumab
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Discovery
Sponsor : University of Cincinnati
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Carboprost Tromethamine
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Discovery
Sponsor : Mankind Pharma
Deal Size : $1,640.0 million
Deal Type : Acquisition
India's Mankind Pharma to Buy Bharat Serums in a $1.6 Billion Deal
Details : Through the acquisition of BSV, Mankind will enhance its pipelines including Endoprost (Carboprost Tromethamine), which is indicated for the treatment of post partum haemorrhage.
Brand Name : Endoprost
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 25, 2024
Lead Product(s) : Carboprost Tromethamine
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Discovery
Sponsor : Mankind Pharma
Deal Size : $1,640.0 million
Deal Type : Acquisition
Lead Product(s) : Undisclosed
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Discovery
Sponsor : Bill & Melinda Gates Foundation
Deal Size : $9.6 million
Deal Type : Funding
Details : The comapany will use the received grant for an integrated program on discovery and early development of novel non-hormonal contraceptive medicines and further optimize the hits to in vivo lead compounds during the hit-to-lead process.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 20, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Discovery
Sponsor : Bill & Melinda Gates Foundation
Deal Size : $9.6 million
Deal Type : Funding
Lead Product(s) : Undisclosed
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Discovery
Sponsor : Evotec
Deal Size : Undisclosed
Deal Type : Partnership
Evotec Partner Celmatix Achieves Milestone For PCOS Drug Programme
Details : Novel PCOS drug target, is largely unknown, genomic studies suggest a strong genetic connection from Celmatix-Evotec Alliance, identified by Celmatix, progresses into hit-identification.
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
January 18, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Discovery
Sponsor : Evotec
Deal Size : Undisclosed
Deal Type : Partnership
LOOKING FOR A SUPPLIER?
Reset All
